HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cultivating Cannabinoid Safety Data In US: Principles, Projects And Problems

Executive Summary

FDA offers guiding principles for research on cannabinoids’ use in food, supplements and lotions and other personal care products. It also identifies challenges to studies that generate robust data about use of the ingredients.

You may also be interested in...



Wisconsin Doctor’s CBD Nasal Sprays, Topical Offered OTC Diagnosed As Unapproved Drugs

Nasadol CBD Nasal Sprays not only are violative for claims unallowed for CBD, but for containing CBD. FDA also warns online pharmacy about fraudulent OTC COVID-19 cure kit.

Bausch Health Has Full Plate While Trimming Debt, Setting Table For Bausch + Lomb Separation

Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.

Church & Dwight Cuts Outlook Due To Rising Costs, Adds Suppliers To Strengthen ‘Weak Links’

“We expect higher input costs and transportation costs to remain elevated for the rest of the year,” says CEO Matthew Farrell. Firms lowers full-year outlook for net sales growth from previous range of 5% to 6% to around 5%.

Topics

UsernamePublicRestriction

Register

RS150873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel